Clinical Trials · NCT01319240
Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 24
- Start date
- Mar 2011
- Locations
- 1 site, Germany
- Primary endpoint
- The area under insulin degludec concentration-time curve